A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. This year’s metric has recorded a Price increase of 37.53%. However, over the past six months, we’ve seen a weaker performance of 121.89%. The price of CBAY fallen by 0.92% over the last 30 days. And in the last five days, it has surged by 0.05%.
Cymabay Therapeutics Inc’s stock market performance has been consistent. The 1-year high for the company’s stock was recorded at $32.49 on 03/21/24, with the lowest value being $7.26 on 06/27/23.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of CBAY Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Cymabay Therapeutics Inc’s current trading price is -0.02% away from its 52-week high, while its distance from the 52-week low is 347.40%. The stock’s price range for this period has been between $7.26 and $32.49. The Healthcare sector company’s shares saw a trading volume of about 1.52 million for the day, which was lower than the average daily volume of 3.78 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Cymabay Therapeutics Inc (CBAY) has experienced a quarterly rise of 43.55% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.73B and boasts a workforce of 101 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 24.23, with a change in price of +17.30. Similarly, Cymabay Therapeutics Inc recorded 3,149,372 in trading volume during the last 100 days, posting a change of +113.99%.
CBAY’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for CBAY stands at 0.39. Similarly, the long-term debt-to-equity ratio is also 0.36.
CBAY Stock Stochastic Average
As of today, the raw stochastic average of Cymabay Therapeutics Inc over the last 50 days is at 99.85%. This shows a increasee from the raw stochastic average of the previous 20 days, which was recorded at 95.35%. Further, the company’s Stochastic %K and %D values for the last 20 days were 96.49% and 96.23%, respectively.
